Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound

Marine Drugs

Volumn 11, Issue 3, 2013, Pages 944-959

  Serova, Maria ^a,b   De Gramont, Armand ^a,b   Bieche, Ivan ^b   Riveiro, Maria Eugenia ^b   Galmarini, Carlos Maria ^c   Aracil, Miguel ^c   Jimeno, José ^c   Faivre, Sandrine ^b   Raymond, Eric ^b  

^a AAREC Filia Research   (France)

^b BEAUJON HOSPITAL   (France)

^c PHARMAMAR S A   (Spain)

Author keywords

E cadherin; ErbB3; Irvalec; Oncosis

Indexed keywords

CISPLATIN; ELISIDEPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FLUOROURACIL; GEMCITABINE; KAHALALIDE F; LAPATINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; OXALIPLATIN; PROTEIN BCL 2; UVOMORULIN; VIMENTIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PROTEIN EXPRESSION;

EID: 84875782334     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11030944     Document Type: Article

References (27)

1. Shilabin, A.G.; Kasanah, N.; Wedge, D.E.; Hamann, M.T. Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: Semisynthetic modifications and antifungal lead-exploration studies. J. Med. Chem. 2007, 50, 4340-4350.
2. Garcia-Rocha, M.; Bonay, P.; Avila, J. The antitumoral compound kahalalide facts on cell lysosomes. Cancer Lett. 1996, 99, 43-50.
3. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Munoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer. Ther. 2003, 2, 863-872.
4. Faircloth, G.T.; Smith, B.; Grant, W.; Jimeno, J.M.; Garcia-Gravalos, L.; Scotto, K.; Shtil, A. Selective antitumor activity of Kahalalide F, a marine-derived cyclic depsipeptide. Proc. Am. Assoc. Cancer Res. 2001, 42, 213.
5. Janmaat, M.; Rodriguez, J.; Jimeno, J.; Kruyt, F.; Giaccone, G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68, 502-510.
6. Ling, Y.H.; Aracil, M.; Jimeno, J.; Perez-Solera, R.; Zoua, Y. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur. J. Cancer 2009, 45, 1855-1864.
7. Teixidó, C.; Arguelaguet, E.; Pons, B.; Aracil, M.; Jimeno, J.; Somoza, R.; Marés, R.; Ramón, Y.; Cajal, S.; Hernández- Losa, J. ErbB3 expression predicts sensitivity to elisidepsin treatment: In vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines. Int. J. Oncol. 2012, 41, 317-324.
8. Varadi, T.; Rosnik, J.; Lisboa, D.; Vereb, G.; Molina-Guijarro, J.M.; Galmarini, C.M.; Szöllosi, J.; Nagy, P. ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur. J. Pharmacol. 2011, 667, 91-99.
9. Molina-Guijarro, J.M.; Macías, Á.; García, C.; Muñoz, E.; García-Fernández, L.F.; David, M.; Núñez, L.; Martínez-Leal, J.F.; Moneo, V.; Cuevas, C.; et al. Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell death in tumor cells. PLoS One 2011, 6, e19042.
10. Herrero, A.B.; Astudillo, A.M.; Balboa, M.A.; Cuevas, C.; Balsinde, J.; Moreno, S. Levels of SCS7/FA2H-Mediated Fatty Acid 2-Hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res. 2008, 68, 9779-9787.
11. Bruce, J.Y.; Geary, D.; de las Heras, B.; Soto, A.; Garcia Paramio, P.; Yovine, A.; Schilsky, R.L.; Undevia, S.D.; Ratain, M.J. Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations. J. Clin. Oncol. 2008, 26, 2513.
12. Faivre, S.J.; Ropert, S.; Coronado, C.; Alcantara, J.; de Miguel, B.; Soto, A.; Szyldergemajn, S.A.; Loussilaho, G.; Mir, O.; Goldwasser, F.; et al. Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 2011, 29, e13097.
13. Sewell, J.M.; Mayer, I.; Langdon, S.P.; Smyth, J.F.; Jodrell, D.I.; Guichard, S.M. The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines. Eur. J. Cancer 2005, 41, 1637-1644.
14. Baselga, J.; Swain, S.M. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9, 463-475.
15. Kono, K.; Takahashi, A.; Amemiya, H.; Ichihara, F.; Sugai, H.; Iizuka, H.; Fujii, H.; Matsumoto, Y. Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int. J. Cancer 2002, 98, 216-220.
16. Ghoul, A.; Serova, M.; Astorgues-Xerri, L.; Bieche, I.; Bousquet, G.; Varna, M.; Vidaud, M.; Phillips, E.; Weill, S.; Benhadji, K.A.; et al. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res. 2009, 69, 4260-4269.
17. Serova, M.; Astorgues-Xerri, L.; Bieche, I.; Albert, S.; Vidaud, M.; Benhadji, K.A.; Emami, S.; Vidaud, D.; Hammel, P.; Theou-Anton, N.; et al. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. Mol. Cancer Ther. 2010, 9, 1308-1317.
18. De Craene, B.; Gilbert, B.; Stove, C.; Bruyneel, E.; van Roy, F.; Berx, G. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res. 2005, 65, 6237-6244.
19. Fritah, A.; Saucier, C.; de Wever, O.; Bracke, M.; Bièche, I.; Lidereau, R.; Gespach, C.; Drouot, S.; Redeuilh, G.; Sabbah, M. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol. Cell Biol. 2008, 28, 1114-1123.
20. Ling, Y.H.; Aracil, M.; Zou, Y.; Yuan, Z.; Lu, B.; Jimeno, J.; Cuervo, A.M.; Perez-Soler, R. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin. Cancer Res. 2011, 17, 5353-5366.
21. Sabbah, M.; Emami, S.; Redeuilh, G.; Julien, S.; Prévost, G.; Zimber, A.; Ouelaa, R.; Bracke, M.; de Wever, O.; Gespach, C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11, 123-151.
22. Arumugam, T.; Ramachandran, V.; Fournier, K.F.; Wang, H.; Marquis, L.; Abbruzzese, J.L.; Gallick, G.E.; Logsdon, C.D.; McConkey, D.J.; Choi, W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69, 5820-5828.
23. Teixidó, C.; Marés, R.; Aracil, M.; Ramón, Y.; Cajal, S.; Hernández-Losa, J. Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines. PLoS One 2013, 8, e53645.
24. Singh, A.; Greninger, P.; Rhodes, D.; Koopman, L.; Violette, S.; Bardeesy, N.; Settleman, J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15, 489-500.
25. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
26. Bièche, I.; Parfait, B.; Laurendeau, I.; Girault, I.; Vidaud, M.; Lidereau, R. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001, 56, 8109-8115.
27. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22, 27-55.